Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs

Aminah Jatoi, Stephen P. Kahanic, Stephen Frytak, Paul Schaefer, Robert L. Foote, Jeff A Sloan, Ronald Carl Petersen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. Methods: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLC patients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. Results: Only nine of 104 patients enrolled over 15 months (four donepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. Conclusion: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLC patients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.

Original languageEnglish (US)
Pages (from-to)66-69
Number of pages4
JournalSupportive Care in Cancer
Volume13
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Small Cell Lung Carcinoma
Vitamin E
Cognition
Placebos
Quality of Life
Cranial Irradiation
donepezil
Cognitive Dysfunction
Double-Blind Method
Dementia
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients : Preliminary results and suggestions for future study designs. / Jatoi, Aminah; Kahanic, Stephen P.; Frytak, Stephen; Schaefer, Paul; Foote, Robert L.; Sloan, Jeff A; Petersen, Ronald Carl.

In: Supportive Care in Cancer, Vol. 13, No. 1, 01.2005, p. 66-69.

Research output: Contribution to journalArticle

@article{c8d19ef5839243718e80429b68e1bf39,
title = "Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs",
abstract = "Background: Up to 90{\%} of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. Methods: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLC patients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. Results: Only nine of 104 patients enrolled over 15 months (four donepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. Conclusion: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLC patients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.",
author = "Aminah Jatoi and Kahanic, {Stephen P.} and Stephen Frytak and Paul Schaefer and Foote, {Robert L.} and Sloan, {Jeff A} and Petersen, {Ronald Carl}",
year = "2005",
month = "1",
doi = "10.1007/s00520-004-0696-0",
language = "English (US)",
volume = "13",
pages = "66--69",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients

T2 - Preliminary results and suggestions for future study designs

AU - Jatoi, Aminah

AU - Kahanic, Stephen P.

AU - Frytak, Stephen

AU - Schaefer, Paul

AU - Foote, Robert L.

AU - Sloan, Jeff A

AU - Petersen, Ronald Carl

PY - 2005/1

Y1 - 2005/1

N2 - Background: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. Methods: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLC patients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. Results: Only nine of 104 patients enrolled over 15 months (four donepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. Conclusion: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLC patients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.

AB - Background: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. Methods: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLC patients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. Results: Only nine of 104 patients enrolled over 15 months (four donepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. Conclusion: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLC patients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.

UR - http://www.scopus.com/inward/record.url?scp=13244267143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244267143&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0696-0

DO - 10.1007/s00520-004-0696-0

M3 - Article

C2 - 15480814

AN - SCOPUS:13244267143

VL - 13

SP - 66

EP - 69

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -